Abstract: The present invention relates to a slow-release solid oral nutraceutical and/or pharmaceutical composition comprising: a core containing a donor of methyl groups and at least one pharmaceutically acceptable excipient, and an outer coating containing shellac and/or a pharmaceutically acceptable salt thereof, magnesium stearate, and at least one pharmaceutically acceptable excipient. The coating of said solid oral composition allows the donor of methyl groups, preferably SAMe and/or a pharmaceutically acceptable salt thereof, to cross intact the gastric barrier and release the same in a continuous and complete manner along the entire digestive tract.

Abstract: This invention relates to solid oral compositions based on SAMe and/or NADH or their salts in association with calcium oxide and/or calcium hydroxide and a process for obtaining them. This invention also relates to a method for stabilising a solid oral composition based on SAMe and/or NADH or their salts, making use of calcium oxide, calcium hydroxide optionally in association with malic acid, glutamic acid, xylitol, calcium sulphate hemihydrate, magnesium oxide and/or mixtures thereof. This invention also relates to the use of SAMe or its salts in association with calcium oxide and/or calcium hydroxide with the possible further addition of melatonin and/or 1-theanine and/or 1-tryptophan and/or 5-hydroxytryptophan for the treatment of depressive states.

Abstract: The object of the present invention is a composition comprising shellac and/or a salt thereof and sodium starch glycolate and at least one physiologically acceptable excipient and a process for obtaining it.

Abstract: The present invention relates to a slow-release solid oral nutraceutical and/or pharmaceutical composition comprising: a core containing a donor of methyl groups and at least one pharmaceutically acceptable excipient, and an outer coating containing shellac and/or a pharmaceutically acceptable salt thereof, magnesium stearate, and at least one pharmaceutically acceptable excipient. The coating of said solid oral composition allows the donor of methyl groups, preferably SAMe and/or a pharmaceutically acceptable salt thereof, to cross intact the gastric barrier and release the same in a continuous and complete manner along the entire digestive tract.

Abstract: Method for producing a tablet and tablet thus produced; the tablet is obtained by direct compression and comprises at least 60% by weight of fructose extracted from grapes; the tablet shows characteristics of colour, friability and cracking off definitely superior with respect to corresponding tablets obtained with fructose of different origin.

Abstract: This invention relates to solid oral compositions based on SAMe and/or NADH or their salts in association with calcium oxide and/or calcium hydroxide and a process for obtaining them. This invention also relates to a method for stabilising a solid oral composition based on SAMe and/or NADH or their salts, making use of calcium oxide, calcium hydroxide optionally in association with malic acid, glutamic acid, xylitol, calcium sulphate hemihydrate, magnesium oxide and/or mixtures thereof. This invention also relates to the use of SAMe or its salts in association with calcium oxide and/or calcium hydroxide with the possible further addition of melatonin and/or 1-theanine and/or 1-tryptophan and/or 5-hydroxytryptophan for the treatment of depressive states.

Abstract: The object of the present invention is a composition shellac and/or a salt thereof and sodium starch glycolate and at least one physiologically acceptable excipient and a process for obtaining it.

Abstract: The present invention refers to new salts of S-adenosyknethionine (SAMe) with improved stability and containing at least 70% by weight of SAMe.

Abstract: The present invention relates to solid dietary and/or nutraceutic pharmaceutical compositions for oral use based on SAMe, or salts thereof, in combination with inositol and/or derivatives thereof and to a process for their preparation. The present invention relates to a method of stabilising a solid composition for oral use based on SAMe or salts thereof, making use of inositol and/or derivatives thereof with the addition of magnesium oxide.

Abstract: The present invention refers to new salts of S-adenosyknethionine (SAMe) with improved stability and containing at least 70% by weight of SAMe.

Abstract: The present invention relates to solid dietary and/or nutraceutic pharmaceutical compositions for oral use based on SAMe, or salts thereof, in combination with inositol and/or derivatives thereof and to a process for their preparation. The present invention relates to a method of stabilising a solid composition for oral use based on SAMe or salts thereof, making use of inositol and/or derivatives thereof with the addition of magnesium oxide. The present invention also relates to the use of SAMe, or salts thereof, in combination with inositol and/or derivatives thereof with the possible further addition of melatonine, St. John's Wort and/or lemon balm for the treatment of depressive states and/or panic syndromes.

Abstract: This invention relates to solid oral compositions based on SAMe and/or NADH or their salts in association with calcium oxide and/or calcium hydroxide and a process for obtaining them. This invention also relates to a method for stabilising a solid oral composition based on SAMe and/or NADH or their salts, making use of calcium oxide, calcium hydroxide optionally in association with malic acid, glutamic acid, xylitol, calcium sulphate hemihydrate, magnesium oxide and/or mixtures thereof. This invention also relates to the use of SAMe or its salts in association with calcium oxide and/or calcium hydroxide with the possible further addition of melatonin and/or 1-theanine and/or 1-tryptophan and/or 5-hydroxytryptophan for the treatment of depressive states.

Abstract: A granular formulation is described, said formulation being based on granules formed by an inner core essentially consisting of at least one pure active component, mixtures of active components or mixtures thereof with suitable inert excipients or pharmaceutically acceptable salts thereof in an amount of between 50% and 90% by weight of the formulation, and by an outer coating essentially consisting of hydrogenated vegetable fats in an amount of between 10% and 50% by weight of the formulation. An example of the selected active component is S-adenosylmethionine. The product according to said formulation can be used, for example, also in the veterinary field for administration by mixing with the feed.

Abstract: The present invention relates to solid dietary and/or nutraceutic pharmaceutical compositions for oral use based on SAMe, or salts thereof, in combination with inositol and/or derivatives thereof and to a process for their preparation. The present invention relates to a method of stabilising a solid composition for oral use based on SAMe or salts thereof, making use of inositol and/or derivatives thereof with the addition of magnesium oxide.